Drugs / MVT-5873
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04883775 | May 2021 → Jan 2025 | malignant pancreatic neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02687230 | Jul 2016 → May 2017 | pancreatic adenocarcinoma | BioNTech SE | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02672917 | Jan 2016 → Aug 2024 | malignant pancreatic neoplasm | BioNTech SE | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT03801915 | Nov 2019 → May 2022 | cholangiocarcinoma, colon carcinoma, metastasis from malignant tumor of colon, pancreatic adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03118349 Background | Jun 2017 → Apr 2018 | pancreatic adenocarcinoma | BioNTech SE | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-11-14 | BioNTech SE | Regulatory BioNTech SE Provides Update on Corporate Progress and Third Quarter 2019 Financial Results biontech.com ↗
Successfully transferred IND for BNT321 to BioNTech. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-11-14 | BioNTech SE | BioNTech SE Provides Update on Corporate Progress and Third Quarter 2019 Financial Results biontech.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVT-5873 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04883775 ↗ |
| Known as | HUMAB-5B1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297791 ↗ |
| Action | Inhibit | “The agent MVT-5873 was designed to block this molecule.” NCT03801915 ↗ |
| Modality | Monoclonal antibody | “a cytotoxic monoclonal antibody targeting carbohydrate antigen 19-9 (CA 19-9)” PMID 32399263 ↗ Apr 2020 |
| Route | Intravenous | “MVT-5873 is administered intravenously as a non-radioactive blocking agent prior to administration of MVT-2163” NCT02687230 ↗ |